merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>The skepticism stems from the significant safety risks, including swelling and bleeding in the brain.</answer>
<question_number>2</question_number>
<answer>It might discourage patients from participating in trials for treatments that could be better.</answer>
<question_number>3</question_number>
<answer>There's no correlation between the removal of amyloid plaques and the clinical response in individual subjects.</answer>
<question_number>4</question_number>
<answer>N/A</answer>
<question_number>5</question_number>
<answer>The cost might be justified by the expectation that patients can stop Kisunla after their plaques are cleared, potentially reducing overall cost and inconvenience.</answer>
<question_number>6</question_number>
<answer>Some experts worry that emphasis on anti-amyloid drugs might discourage patients from participating in trials for treatments that could be better.</answer>
<question_number>7</question_number>
<answer>Kisunla can be discontinued after it clears the amyloid protein, reducing the overall cost and inconvenience of the treatment as well as the risk of side effects.</answer>
<question_number>8</question_number>
<answer>Amyloid</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>
<question_number>10</question_number>
<answer>Trial participants with intermediate tau levels declined more slowly on donanemab than those with high levels.</answer>